Unicycive Therapeutics, Inc., (UNCY): Price and Financial Metrics


Unicycive Therapeutics, Inc., (UNCY): $0.85

0.01 (+1.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add UNCY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

UNCY Stock Price Chart Interactive Chart >

Price chart for UNCY

UNCY Price/Volume Stats

Current price $0.85 52-week high $8.73
Prev. close $0.84 52-week low $0.62
Day low $0.80 Volume 3,500
Day high $0.90 Avg. volume 118,897
50-day MA $1.03 Dividend yield N/A
200-day MA $1.91 Market Cap 12.77M

Unicycive Therapeutics, Inc., (UNCY) Company Bio


Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.


UNCY Latest News Stream


Event/Time News Detail
Loading, please wait...

UNCY Latest Social Stream


Loading social stream, please wait...

View Full UNCY Social Stream

Latest UNCY News From Around the Web

Below are the latest news stories about Unicycive Therapeutics Inc that investors may wish to consider to help them evaluate UNCY as an investment opportunity.

Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two abstracts supporting the potential efficacy and safety of Renazorb (lanthanum dioxycarbonate) to be presented as posters at the National Kidney Foundation (NKF) Spring Clinical Meeting taking place April 6-10, 2022 in Boston. Renazorb is a second-generation lanthanum-based phosphate binding agent utilizing proprietary nan

Yahoo | February 2, 2022

Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

Yahoo | January 10, 2022

Unicycive Therapeutics pops 6% after receiving FDA guidance on Renazorb regulatory pathway

No summary available.

Seeking Alpha | November 29, 2021

Unicycive Therapeutics Receives FDA Guidance On Renazorb Regulatory Pathway

Unicycive Therapeutics Inc (NASDAQ: UNCY ) updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate). Renazorb is a second-generation lanthanum-based phosphate-binding agent utilizing proprietary nanoparticle technology for hyperphosphatemia in patients with chronic kidney disease (CKD). In a recent Type C interaction with the FDA, Unicycive sought the FDA''s feedback on the sufficiency of the Renazorb Full story available on Benzinga.com

Benzinga | November 29, 2021

Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway

LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum

PR Newswire | November 29, 2021

Read More 'UNCY' Stories Here

UNCY Price Returns

1-mo -2.38%
3-mo -38.85%
6-mo -60.28%
1-year N/A
3-year N/A
5-year N/A
YTD -58.74%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.525 seconds.